Sarepta Therapeutics (SRPT) had the highest return between August 11, 2016 and September 30, 2016 by a mid-cap US stock, returning 152.8%.
| ASSET | DATE | % RETURN |
|---|---|---|
Sarepta Therapeutics (SRPT) | 8/11/2016 - 9/30/2016 | 152.82% |
Alpha Metallurgical Resources (AMR) | 8/11/2016 - 9/30/2016 | 147.41% |
Alphatec (ATEC) | 8/11/2016 - 9/30/2016 | 123.81% |
Merus (MRUS) | 8/11/2016 - 9/30/2016 | 98.93% |
Comstock Resources (CRK) | 8/11/2016 - 9/30/2016 | 88.18% |
Impinj (PI) | 8/11/2016 - 9/30/2016 | 84.15% |
PTC Therapeutics (PTCT) | 8/11/2016 - 9/30/2016 | 82.66% |
Protagonist Therapeutics (PTGX) | 8/11/2016 - 9/30/2016 | 76.08% |
Wave Life Sciences (WVE) | 8/11/2016 - 9/30/2016 | 70.54% |
Bank of NT Butterfield & Son (NTB) | 8/11/2016 - 9/30/2016 | 66.69% |
Veracyte (VCYT) | 8/11/2016 - 9/30/2016 | 52.51% |
Catalyst Pharmaceuticals (CPRX) | 8/11/2016 - 9/30/2016 | 43.5% |
Lantheus (LNTH) | 8/11/2016 - 9/30/2016 | 43.25% |
TG Therapeutics (TGTX) | 8/11/2016 - 9/30/2016 | 40.47% |
Genworth Financial (GNW) | 8/11/2016 - 9/30/2016 | 40.11% |
Spyre Therapeutics (SYRE) | 8/11/2016 - 9/30/2016 | 39.35% |
HealthEquity (HQY) | 8/11/2016 - 9/30/2016 | 33.51% |
AAR (AIR) | 8/11/2016 - 9/30/2016 | 31.87% |
Skyline (SKY) | 8/11/2016 - 9/30/2016 | 31% |
Civitas Resources (CIVI) | 8/11/2016 - 9/30/2016 | 30.77% |
Bancorp (TBBK) | 8/11/2016 - 9/30/2016 | 30.22% |
APA (APA) | 8/11/2016 - 9/30/2016 | 29.45% |
Axos Financial (AX) | 8/11/2016 - 9/30/2016 | 28.59% |
Itron (ITRI) | 8/11/2016 - 9/30/2016 | 28.15% |
Box (BOX) | 8/11/2016 - 9/30/2016 | 27.61% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
